WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

The nasal spray can be given to people who haven’t seen improvements in their depression after taking at least two oral medications, according to Johnson & Johnson. The main ingredient for the ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

Google to Invest Fresh $1 Billion in OpenAI Rival Anthropic, FT Reports (Reuters) -Google is making a fresh investment of more than $1 billion into AI startup Anthropic, the Financial Times ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

A doctor may prescribe ketorolac (Toradol), an NSAID available as a nasal spray, to help manage migraine attacks that cause severe pain. They may also recommend ketorolac as a rescue medication if ...

Jan 18 (Reuters) - Commerzbank (CBKG.DE), opens new tab is exploring cutting thousands of jobs as it seeks to fend off an unwanted approach from Italy's UniCredit (CRDI.MI), opens new tab, the ...